Biochemical markers for brain damage

Neurosurgery Quarterly

Volumn 11, Issue 3, 2001, Pages 173-180

  Ikeda, Yukio ^a   Hayashi, Munetaka ^a   Dohi, Kenji ^a   Matsumoto, Kiyoshi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biochemical markers; Neuronspecific enolase; Rain damage; S 100 protein

Indexed keywords

BIOCHEMICAL MARKER; CREATINE KINASE BB; MYELIN BASIC PROTEIN; NEURON SPECIFIC ENOLASE; PROTEIN S 100; PROTEIN S100B; UNCLASSIFIED DRUG;

BRAIN INJURY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; HUMAN; MEDICAL DECISION MAKING; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ASSAY; REVIEW; STROKE; SUBARACHNOID HEMORRHAGE; TREATMENT PLANNING;

EID: 0034876039     PISSN: 10506438     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013414-200109000-00001     Document Type: Review

References (80)

1. Markers of cerebral ischemia after cardiac surgery
2. S-100 protein plasma levels after aneurysmal subarachnoid haemorrhage
3. Pathophysiology of cerebrospinal fluid in head injury: Part 2. Biochemical markers for central nervous system trauma
4. Traumatic brain damage in minor head injury: Relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome
5. The S-100: A protein family in search of a function
6. The S100 protein family: History, function, and expression
7. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorder
8. S-100b protein serum levels after controlled cortical impact injury in the rat
9. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage
10. Increased serum concentrations of protein S-100 after minor head injury: A biochemical serum marker with prognostic value?
11. Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury: Case report
12. Management of minor head injury: The value of early computed tomography and serum protein S-100 measurements
13. Neuropsychological function in patients with increased serum levels of protein S-100 after minor head injury
14. Correlation of computed tomography findings and serum brain damage markers following severe head injury
15. Jugular venous and arterial concentrations of serum S-100b protein in patients with severe head injury: A pilot study
16. Serum S-100b protein in severe head injury
17. Fatal secondary increase in serum S-100b protein after severe head injury
18. Comparison of serial S-100 and NSE serum measurements after severe head injury
19. S-100 serum levels after minor and major head injury
20. Protein S-100b and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury
21. Temporal profile of release of neurobiochemical markers of brain damage after traumatic brain injury is associated with intracranial pathology as demonstrated in cranial computerized tomography
22. Serum markers of brain damage and outcome prediction in patients after severe head injury
23. S-100 protein plasma levels after aneurysmal susbarachnoid hemorrhage
24. S-100 protein in cerebrospinal fluid of patients with subarachnoid haemorrhage: A potential marker of brain damage
25. S-100 protein in cerebrospinal fluid after aneurysmal subarachnoid haemorrhage: Relation to functional outcome, late CT and SPECT changes, and signs of higher cortical dysfunction
26. S-100 protein and calmodulin levels in cerebrospinal fluid after subarachnoid hemorrhage
27. Measurement of S-100b in cerebrospinal fluid among SAH cases: Prediction of outcome
28. S-100 protein: Serum marker of focal brain damage after ischemic territorial MCA infarction
29. S-100 protein and neuron-specific enolase concentration volume and prognosis in acute ischemic stroke
30. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction
31. Serum S-100 protein, relationship to clinical outcome in acute stroke
32. Leakage of brain-originated proteins in peripheral blood: Temporal profile and diagnostic value in early ishemic stroke
33. Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage
34. Cerebral complications after cardiac surgery assessed by S-100 and NSE levels in blood
35. Elevated serum levels of S-100 after deep hypothermic arrest correlate with duration of circulatory arrest
36. Serum S-100 protein levels after pediatric cardiac operations: A possible new marker for postperfusion cerebral injury
37. Increased serum levels of the S-100 protein are associated with hypoxic brain damage after cardiac arrest
38. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia
39. A contrastive analysis of release patterns of biochemical markers of brain damage after coronary artery bypass grafting and valve replacement and their association with the neurobehavioral outcome after cardiac surgery
40. Neuropsychological change and S-100 protein release in 130 unselected patients undergoing cardiac surgery
41. Neurobehavioral outcome prediction after cardiac surgery: Role of neurobiochemical markers of damage to neuronal and glial brain tissues
42. Neuron-specific enolase, a clinically useful marker for neurons and neuroendocrine cells
43. Time course of serum neuron-specific enolase: A predictor of neurological outcome in patients resuscitated from cardiac arrest
44. The significance of neuron specific enolase levels in cerebrospinal fluid and serum after experimental traumatic brain damage
45. Significance of serum neuron-specific enolase levels after head injury
46. Diagnostic significance of serum neuron-specific enolase and myelin basic protein assay in patients with acute head injury
47. Neuron-specific enolase as an aid to outcome prediction in head injury
48. Prognostic value of serum neuron-specific enolase levels after head injury
49. Serum neuron-specific enolase levels after subarachnoid hemorrhage
50. Measurement of serum neuron-specific enolase levels after subarachnoid hemorrhage and intracerebral hemorrhage
51. Neuron-specific enolase in gerbil brain and serum after transient cerebral ischemia
52. Neuron-specific enolase increase in cerebral and systemic circulation following focal ischemia
53. Experimental brain ischemia; neuron-specific enolase level in cerebrospinal fluid as an index of neuronal damage
54. Neuron-specific enolase is a marker of cerebral ischemia and infarct size in rat cerebrospinal fluid
55. Enolase isoenzymes in the cerebrospinal fluid of patients with diseases of the nervous system
56. Cerebrospinal fluid enolase in stroke
57. Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid
58. Levels of serum and cerebrospinal fluid enolase in patients with cerebral vascular disease and other neurological diseases
59. Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay
60. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases
61. Serum neuron-specific enolase as an indicator of stroke volume
62. Time course of serum neuron-specific enolase: A predictor of neurological outcome in patients resuscitated from cardiac arrest
63. Changes of neuron-specific enolase concentration in plasma after cardiac arrest and resuscitation
64. A comparison of the prognostic value of neuron-specific enolase serum levels and somatosensory evoked potentials in 13 reanimated patients
65. Serum S-100 and neuron-specific enolase for prediction of regaining consciousness after global cerebral ischemia
66. Serum neuron-specific enolase as early predictor of outcome after cardiac arrest
67. Quantification of cerebral infarct size by creatine kinase BB isoenzyme
68. Cerebrospinal fluid creatine kinase BB isoenzyme activity and neurologic prognosis after cardiac arrest
69. Creatine kinase BB isoenzyme in CSF in neurologic disease
70. Sequential changes in serum creatine phosphokinase isoenzyme activity and correlation with prognosis in patients with acute head injury
71. Radioimmunoassay of the brain type isoenzyme of creatine phosphokinase (CK-BB): A new diagnostic tool in the evaluation of patients with head injury
72. Increased serum creatine kinase BB anal neuron specific enolase following head injury indicates brain damage
73. Cerebrospinal fluid creatine kinase-BB isoenzyme activity and outcome after subarachnoid hemorrhage
74. Cerebrospinal fluid creatine kinase-BB activity: A perspective
75. Effects of therapeutic hypothermia on activity of some enzymes in cerebrospinal fluid of patients with anoxic ischemic brain injury
76. Pathophysiology of cerebrospinal fluid in head injury: Part 1. Pathological changes in cerebrospinal fluid solute composition after traumatic injury
77. Cerebrospinal fluid myelin basic protein as a prognostic marker in patients with head injury
78. Serum myelin basic protein assay in diagnosis and prognosis of patients with head injuries
79. Serum myelin basic protein, clinical responsiveness, and outcome of head injury
80. Increase in myelin basic protein in CSF after brain surgery